South Korea’s SK Plasma on Tuesday began commercial rollout of Albumin 20 percent Inj., a therapeutic substance derived from human blood, and its delivery to Afghanistan military and police forces under the command of the North Atlantic Treaty Organization (NATO).

SK Plasma is the first Korean pharmaceutical company to supply medicines to the military alliance.

In June, SK Plasma was selected as the final supplier of the blood product in a global bidding organized by the NATO Procurement Agency.

The destination of SK Plasma’s albumin products is Kabul, the capital of Afghanistan where military and police suffer from an absolute shortage of essential medicines due to long civil wars.

SK Plasma`s albumin is a leading blood product indicated for the treatment of hypoalbuminemia and hemorrhagic shock. SK Plasma has produced albumin since 1984. SK Plasma will accelerate its global expansion in the future as the latest supply proves the excellence and global competitiveness of its blood products, said the company’s CEO Kim Yoon-ho. SK Plasma plans to continue to participate in bidding for the NATO and UN-affiliated organizations.

SK Plasma has been dedicated to blood products since it was spun off from SK Chemicals in 2015. Its production facility for blood products covers 600,000 liters per year. It was selected as the final supplier of immunoglobulin IVIG-SN in a bid for Brazil in September last year.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]